Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

2

Days Left

GDRX

GoodRx Holdings, Inc.

Deadline

June 21 2024

Class Period

9/23/22 - 11/8/22

Allegations

(1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx’s total prescription transactions revenue (the Company’s primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx’s revenues for purchases at Kroger’s pharmacies; and (3) as a result, defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

9/23/22 - 11/8/22

Deadline

June 21 2024

Learn More

5

Days Left

LNC

Lincoln National Corporation

Deadline

June 24 2024

Class Period

11/4/20 - 11/2/22

Allegations

(1) the Company was experiencing a decline in its variable universal life insurance business; (2) as a result, the goodwill associated with the life insurance business was overstated; (3) as a result, the Company’s policy lapse assumptions were outdated; (4) as a result, the Company’s reserves were overstated; (5) as a result, the Company’s reported financial results and financial statements were misstated; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/20 - 11/2/22

Deadline

June 24 2024

Learn More

5

Days Left

CMP

Compass Minerals International, Inc.

Deadline

June 24 2024

Class Period

11/29/23 - 3/22/24

Allegations

(1) Compass Minerals overstated the likelihood that it would be awarded a renewed U.S. Forest Service contract for the use of its proprietary magnesium chloride-based aerial fire retardants for the 2024 fire season, as a result of safety issues presented by its fire retardant; (2) Compass Minerals materially overstated the extent to which testing had confirmed that its fire retardants were safe; and (3) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

11/29/23 - 3/22/24

Deadline

June 24 2024

Learn More

5

Days Left

ADSK

Autodesk, Inc.

Deadline

June 24 2024

Class Period

6/1/23 - 4/16/24

Allegations

(1) Autodesk, Inc. lacked adequate internal controls as a result of issues with its free cash flow and non-GAAP operating margin practices; and (2) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

6/1/23 - 4/16/24

Deadline

June 24 2024

Learn More

6

Days Left

EXAI

Exscientia plc

Deadline

June 25 2024

Class Period

3/23/22 - 2/12/24

Allegations

(i) Andrew Hopkins, the Company's former Chief Executive Officer, had engaged in improper relationships with employees that were inconsistent with the Company’s standards and values; (ii) David Nicholson, former Chairman of the Company’s Board of Directors, had prior knowledge of Hopkins’s relationships and had improperly addressed Hopkins’s misconduct without consulting the Board of Directors; (iii) the Company’s maintenance and enforcement of its Code of Business Conduct and Ethics was inadequate to safeguard against the foregoing conduct; (iv) the foregoing failures subjected the Company to a heightened risk of disruptive leadership transitions and/or reputational harm; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/23/22 - 2/12/24

Deadline

June 25 2024

Learn More

6

Days Left

AKRO

Akero Therapeutics, Inc.

Deadline

June 25 2024

Class Period

9/13/22 - 10/9/23

Allegations

(i) approximately 20% of the patients enrolled in the SYMMETRY study, a trial that purportedly tested efruxifermin ("EFX") in patients with nonalcoholic steatohepatitis (“NASH”) -induced cirrhosis, had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study’s design, materially influencing the study’s potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not rule out potential causes of each patient’s cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

Class Period

9/13/22 - 10/9/23

Deadline

June 25 2024

Learn More

9

Days Left

MBUU

Malibu Boats, Inc.

Deadline

June 28 2024

Class Period

11/4/22 - 4/11/24

Allegations

(1) Malibu Boats had engaged in an “elaborate scheme to over manufacture and pump nearly $100 million of its highest priced, highest margin, slow moving boat inventory into fifteen Tommy’s dealerships”; (2) as a result, the Company artificially inflated Malibu’s sales performance, market share, and stock value; (3) the Company was withholding certain incentives and rebates from its dealers; (4) as a result of the foregoing, the Company faced substantial risk of litigation from one of its top dealers, Tommy’s; (5) the Company’s CEO departed due to his role in this scheme; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/22 - 4/11/24

Deadline

June 28 2024

Learn More

12

Days Left

GL

Globe Life Inc. f/k/a Torchmark Corporation

Deadline

July 1 2024

Class Period

5/8/19 - 4/10/24

Allegations

According to the complaint, throughout the Class Period, Globe Life reported consistent premium revenue growth at the Company, led by consistent premium revenue growth at American Income Life Insurance Company (“AIL”). The Company also represented that its employees adhered to a code of conduct that expressly prohibited various forms of misconduct, and which required that all Globe Life employees comply with relevant laws and regulations, purportedly ensuring that the Company would maintain a workplace free from violence, threatening behavior, and illegal drugs. In truth, Globe Life was engaged in wide-spread insurance fraud, therefore inflating Globe Life’s financial results. In addition, Globe Life permitted a culture of unchecked sexual harassment, in direct contravention of the Company’s Code of Conduct. As a result of defendants’ misrepresentations, shares of Globe Life common stock traded at artificially inflated prices throughout the Class Period.

Class Period

5/8/19 - 4/10/24

Deadline

July 1 2024

Learn More

12

Days Left

EQIX

Equinix, Inc.

Deadline

July 1 2024

Class Period

5/3/19 - 3/24/24

Allegations

(1) Equinix manipulated its financials to reduce operational expenses and boost Adjusted Funds From Operations (“AFFO”); (2) Equinix oversold power capacity and did not warn of the risks associated with this practice; (3) Equinix lacked adequate internal controls; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

5/3/19 - 3/24/24

Deadline

July 1 2024

Learn More

13

Days Left

INTC

Intel Corporation

Deadline

July 2 2024

Class Period

1/25/24 - 4/25/24

Allegations

(1) the growth of Intel Foundry Services was not indicative of revenue growth reportable under the Internal segment; (2) the Foundry experienced significant operating losses in 2023; (3) the Foundry experienced a decline in product profit driven by lower internal revenue; (4) as a result the Foundry model would not be a strong tailwind to the Company’s IFS strategy; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

1/25/24 - 4/25/24

Deadline

July 2 2024

Learn More

16

Days Left

AXTI

AXT, Inc.

Deadline

July 5 2024

Class Period

3/24/21 - 4/3/24

Allegations

(1) AXT, Inc. overstated its property holdings; (2) the Company did not disclose that the attempted listing of an AXT, Inc. subsidiary in China had reportedly failed; (3) AXT, Inc. routinely engaged in environmental violations and unsafe business practices; (4) AXT, Inc.’s production declined in 2023; and (5) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

3/24/21 - 4/3/24

Deadline

July 5 2024

Learn More

16

Days Left

ALT

Altimmune, Inc.

Deadline

July 5 2024

Class Period

12/1/23 - 4/26/24

Allegations

(i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

12/1/23 - 4/26/24

Deadline

July 5 2024

Learn More

20

Days Left

LI

Li Auto Inc.

Deadline

July 9 2024

Class Period

2/26/24 - 5/20/24

Allegations

(i) Li Auto had overstated the demand for its vehicles and the efficacy of its operating strategy in launching its battery electric minivan, Li MEGA; (ii) accordingly, the Company was unlikely to meet its Q1 2024 vehicle deliveries estimate; (iii) the foregoing, once revealed, was likely to have a material negative impact on the Company’s financial condition; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/26/24 - 5/20/24

Deadline

July 9 2024

Learn More

23

Days Left

NARI

Inari Medical, Inc.

Deadline

July 12 2024

Class Period

2/23/22 - 2/28/24

Allegations

(i) the Company deceived the investing public, including plaintiff; (ii) cause the market price of Inari common stock to trade above its true value; and (iii) cause plaintiff as well as other class members to purchase or otherwise acquire Inari common stock at artificially inflated prices that did not reflect the stock’s true value during the class period. In furtherance of their unlawful scheme, plan, or course of conduct, defendants took the actions alleged herein.

Class Period

2/23/22 - 2/28/24

Deadline

July 12 2024

Learn More

23

Days Left

SPT

Sprout Social, Inc.

Deadline

July 12 2024

Class Period

11/2/23 - 5/2/24

Allegations

(1) the Company’s sales and revenue growth were not indicative of the Company’s growth as it transitioned to an enterprise sales cycle; (2) the Company faced integration challenges with its acquisition of Tagger, a leading influencer marketing and social intelligence platform; (3) as a result, the Company was “self inducing sales headwinds;” (4) as a result, the Company would revise fiscal year 2024 revenue guidance; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/2/23 - 5/2/24

Deadline

July 12 2024

Learn More

26

Days Left

UNH

UnitedHealth Group Inc.

Deadline

July 15 2024

Class Period

3/14/22 - 2/27/24

Allegations

According to the filed complaint, defendants made false statements and/or concealed that: In truth, UnitedHealth never established proper firewalls between it's complementary businesses, Optum and UnitedHealthcare as required by its own policy, and as it told the court in the antitrust action, the DOJ and investors it would do. Firewalls were never properly created for certain business applications. Despite assurances to the contrary, there was never a meaningful technological separation between Optum and UnitedHealthcare that prevented the sharing of customer sensitive information.

Class Period

3/14/22 - 2/27/24

Deadline

July 15 2024

Learn More

27

Days Left

TDOC

Teladoc Health, Inc.

Deadline

July 16 2024

Class Period

11/2/22 - 2/20/24

Allegations

According to the complaint, on February 20, 2024, Teladoc announced its fourth quarter and full year results for the period ended December 31, 2023. The announcement disclosed that Teladoc had experienced substantially less growth than previous forecasted. The Company also disclosed that it was expecting decreased revenue for its BetterHelp segment, an online counseling service. Analysts attributed this trend to BetterHelp’s market saturation and increased advertising costs causing a rise the cost of customer acquisitions. Following the release of the earnings report, TDOC shares fell $4.85/share, or 23.6%, overnight.

Class Period

11/2/22 - 2/20/24

Deadline

July 16 2024

Learn More

27

Days Left

VSTS

Vestis Corporation

Deadline

July 16 2024

Class Period

10/2/23 - 5/1/24

Allegations

(1) Aramark, a company providing food service and facilities management, had historically underinvested in the business that became Vestis; (2) Vestis operated with outdated facilities and an underperforming sales force; (3) Vestis’s outdated facilities and underperforming sales force led to “service gaps” that had impeded the Company’s levers of growth and had resulted in customer attrition; and (4) as a result of the above, defendants’ statements about Vestis’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

10/2/23 - 5/1/24

Deadline

July 16 2024

Learn More

33

Days Left

CMBM

Cambium Networks Corporation

Deadline

July 22 2024

Class Period

5/8/23 - 1/18/24

Allegations

(1) there was a buildup of inventory in the Company’s distribution channels; (2) the Company and its distributors were reasonably likely to offer aggressive discounts to reduce the high channel inventories; (3) the Company’s revenue would decline sequentially until the excess channel inventory was sold through; (4) Cambium was likely to incur significant charges to writedown excess and obsolete inventory; (5) as a result of the foregoing, the Company’s fiscal 2023 revenue and earnings would be adversely affected; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/8/23 - 1/18/24

Deadline

July 22 2024

Learn More

33

Days Left

BIIB

Biogen Inc.

Deadline

July 22 2024

Class Period

2/3/22 - 2/13/24

Allegations

(i) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (ii) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (iv) the foregoing subjected the Company to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm; (v) Biogen overstated the strength of its Alzheimer’s disease related product portfolio, including the its joint efforts and success with pharmaceutical company, Eisai, in launching and providing access to Leqembi; (vi) Biogen also downplayed the negative impact that the Reata Acquisition would have on its FY 2023 non-GAAP diluted EPS; (vii) all the foregoing were likely to have a significant negative impact on Biogen’s 2023 results; and (viii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/3/22 - 2/13/24

Deadline

July 22 2024

Learn More

34

Days Left

FSLY

Fastly, Inc.

Deadline

July 23 2024

Class Period

2/15/24 - 5/1/24

Allegations

(i) contrary to its representations to investors, Fastly was in fact experiencing a significant deceleration in growth among its largest customers and was losing the increased market share it had gained as a result of the 2023 content delivery network consolidation trend; (ii) the foregoing issues were likely to have a material negative impact on the Company’s revenue growth; (iii) accordingly, the Company was unlikely to meet its own previously issued revenue guidance for FY 2024; (iv) as a result, the Company’s financial position and/or prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/15/24 - 5/1/24

Deadline

July 23 2024

Learn More

40

Days Left

ENPH

Enphase Energy, Inc.

Deadline

July 29 2024

Class Period

2/7/23 - 4/25/23

Allegations

According to the complaint, on April 25, 2023, Enphase issued a press release announcing its first quarter earnings. In pertinent part, defendants announced revenue in the United States had decreased by approximately 9% attributing it to macroeconomic conditions. Additionally, defendants put out a weak second quarter outlook for 2023 where revenue was estimated to be within the range of $700 million to $750 million. Following this news, the price of Enphase’s common stock declined dramatically. From a closing market price of $220.60 per share on April 25, 2023, Enphase’s stock price fell to $163.83 per share on April 26, 2023, a decline of nearly 26% in the span of just a single day.

Class Period

2/7/23 - 4/25/23

Deadline

July 29 2024

Learn More

41

Days Left

RIVN

Rivian Automotive, Inc.

Deadline

July 30 2024

Class Period

8/12/22 - 2/21/24

Allegations

(i) Rivian had overstated demand for its products, as well as its ability to withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s business was experiencing reduced demand and increased customer cancellations as a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order bank had significantly deteriorated; (iv) all the foregoing was likely to, and did, negatively impact the Company’s anticipated earnings and vehicle production targets for 2024; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

8/12/22 - 2/21/24

Deadline

July 30 2024

Learn More

41

Days Left

HTZ

Hertz Global Holdings, Inc.

Deadline

July 30 2024

Class Period

4/27/23 - 4/24/24

Allegations

(i) Hertz had downplayed the financial impact of vehicle depreciation, and/or overstated its ability to track and manage vehicle depreciation; (ii) demand for Hertz’s EVs was not as strong as Defendants had led investors to believe; (iii) Hertz had too many vehicles, particularly EVs, in its fleet to remain profitable; (iv) as a result of all the foregoing, Hertz was likely to incur significant losses on the disposition of both its ICE vehicles and EVs; (v) all the foregoing was likely to, and did, have a significant negative impact on Hertz’s financial results; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/27/23 - 4/24/24

Deadline

July 30 2024

Learn More

44

Days Left

HUM

Humana Inc.

Deadline

August 2 2024

Class Period

7/27/22 - 1/24/24

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Specifically, defendants downplayed pressures on the Company’s adjusted earnings per share, resulting from increased medical costs associated with pent-up demand for healthcare procedures which contrary to the Company’s assurances, resulted in increased utilization rates and costs.

Class Period

7/27/22 - 1/24/24

Deadline

August 2 2024

Learn More

47

Days Left

MRNS

Marinus Pharmaceuticals, Inc.

Deadline

August 5 2024

Class Period

3/17/21 - 5/7/24

Allegations

(1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

3/17/21 - 5/7/24

Deadline

August 5 2024

Learn More

48

Days Left

GRTS

Gritstone bio, Inc.

Deadline

August 6 2024

Class Period

3/9/23 - 2/29/24

Allegations

(i) the Company would be unable to launch the Phase 2b CORAL Study, it's approved COVID-19 vaccine, in the timeframe it had represented to investors; (ii) the foregoing would impair Gritstone’s ability to obtain external funding in connection with the Study, thereby negatively affecting Gritstone’s ability to maintain its balance sheet and cash position; (iii) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products; (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/9/23 - 2/29/24

Deadline

August 6 2024

Learn More

54

Days Left

LW

Lamb Weston Holdings, Inc.

Deadline

August 12 2024

Class Period

7/25/23 - 4/3/24

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: In truth, defendants knew of, or recklessly disregarded, problems associated with the Enterprise Resource Planning (ERP) system that would hinder its successful implementation. Despite those issues, Lamb Weston pushed ahead with its implementation of an ERP system that was not ready to go live, knowing that a premature roll-out would have a material negative impact on the Company’s business and operations. As a result, the statements concerning its business, operations, and prospects, including its financial guidance for fiscal 2024, lacked a reasonable factual basis. In addition, to the extent the Company purported to warn of risks regarding the negative impacts from an unsuccessful implementation of the ERP system, defendants omitted that such risks had already begun to materialize.

Class Period

7/25/23 - 4/3/24

Deadline

August 12 2024

Learn More

54

Days Left

RBLX

Roblox Corporation

Deadline

August 12 2024

Class Period

11/15/23 - 5/8/24

Allegations

According to the complaint, on February 7, 2024, Roblox – the publisher of the Minecraft video game – issued its FY 2024 fiscal guidance. It was the first time Roblox issued a fiscal guidance to investors. Then, on May 9, 2023, Roblox hosted its quarterly earnings call and slashed its guidance for FY 2024. Management blamed changes in player engagement for the guidance reduction. Analysts expressed dismay at the rapidly reduced guidance, with one analyst noting Roblox made the cut “at one of its first real opportunities to do so.” Other analysts reported the reduced guidance “may raise concerns regarding management’s visibility into core bookings growth” and the Company “will be burdened by a management credibility issue over the near term.” Following the earnings call, RBLX shares fell $8.61, or 22% overnight.

Class Period

11/15/23 - 5/8/24

Deadline

August 12 2024

Learn More

54

Days Left

TWOU

2U, Inc.

Deadline

August 12 2024

Class Period

2/9/22 - 2/12/24

Allegations

(1) the Company was unable to sustain relationships with key universities and organizations; (2) as a result, certain degree programs and partnerships failed to materialize or were cancelled; (3) the Company’s transition to a platform company would lead to a decrease in full course equivalent enrollments; (4) accordingly, the Company had overstated the stability and/or longevity of its contractual agreements and/or revenue sources; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/9/22 - 2/12/24

Deadline

August 12 2024

Learn More

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Innoviz Shareholders will be Represented by Levi & Korsinsky & Pomerantz
Lucid Alternative Fund, LP v. Innoviz Technologies Ltd., et al., 1:24-cv-01971-AT is a lawsuit currently pending in the United States District Court for the Southern District of New York. The action was filed on behalf of investors in Innoviz Technologies Ltd. (NASDAQ: INVZ) who allegedly suffered losses due to securities fraud by the company. On...Read more

June 7, 2024

Learn More

Levi & Korsinsky Ranked Among the Top 50 Plaintiffs' Firms of 2023
Levi & Korsinsky (“L&K”) has once again been recognized by Institutional Shareholder Services Securities Class Action Services (“ISS SCAS”) as one of the top 50 plaintiffs’ firms in the United States, recovering over $133 million for investors in securities-related class action settlements in 2023. On April 22, 2024, ISS SCAS released its “Top Plaintiff Law...Read more

May 14, 2024

Learn More

Lantronix, Inc. Lawsuit Proceeds with Selection of Co-Lead Plaintiffs
Neilsen v. Lantronix, Inc., et al., 8:24-cv-00385-FWS-JDE is a lawsuit currently pending in the United States District Court for the Central District of California. The action was filed on behalf of investors in Lantronix, Inc. (NASDAQ: LTRX) who allegedly suffered losses due to securities fraud by the company. On May 7, 2024, United States District...Read more

May 13, 2024

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys